“Sir, Wagan Cam Karen Ki Dai …”: Doctors were immersed in $ 16,000 to lose weight Jab hit India

Rahul Paxi cannot seize a break these days. The waiting room in a Mumbai diabetes specialist is heading towards the same story every time someone takes his clinic. “Sir Wagan Kam Carney Ki Nay Davai I Hai, Wah Shoro Car Sakti Hin Kia, losing weight to me?”

India’s obsession with the new injection of $ 16,000 a month began.

“It is not a magical injection for everyone,” Dr. Backy explains quickly on X. “Without lifestyle changes – a constantly balanced diet, walking/regular exercises, and force training – may not give the desired results. Using appropriate patients under the supervision of doctors is the key.”

This injection that causes all the ducts is mounjaro (Tirzepatide), which is just presented by the Pharmaceutical giant ELI Lilly in India, ahead of Wegovy of its opponent Novo Nordisk. Marketing in the first place for diabetes and weight loss significantly, the price is 4,375 dollars compared to a 5 mg vial, which costs patients about $ 16,000 per month – an exhibition of India, but is accessible to everyone compared to its American cost of more than $ 1,000 per month.

Dr. Manisha Aura, director of CK BIRLA Hospital, explains her attractiveness in the Indian Express story: Mountjaro simulating two GLP-1 and GIP-GP-to control appetite, stabilize blood sugar, and slow digestion, which leads to impressive weight loss for up to 20 kg in 72 weeks.

But this strong injection is not without risks. Dr. Aroura clearly warns: “The common side effects are the issues of the digestive system such as nausea, vomiting, diarrhea and acid apostasy. In some cases, severe diarrhea can lead to dehydration and acute kidney injury.”

Rapid weight loss can also lead to gallstones and gallbladder.

Who is the perfect candidate? Adults who fight type 2 of diabetes, or those who suffer from significant weight gain, or individuals with insulin resistance do not respond well to other treatments. However, the drug is outside the borders for pregnant women, children, type 1 diabetes, and individuals with the history of thyroid cancer, pancreatitis, or severe digestive disorders.

Madness is not surprising given the obesity epidemic and diabetes in India.

Diabetes can rise to 124 million by 2045, and about a quarter of Indian adults are already overweight or obese.